Cancer: Drug with new approach on impeding DNA repair shows promise in first clinical trial
Berzosertib, an ATR-targeting drug, improves progression-free survival in combination with chemotherapy in patients with high-grade serous ovarian cancer.
Read Original Article: Cancer: Drug with new approach on impeding DNA repair shows promise in first clinical trial »
